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Abstract
Background: Real-life registry data reveal approximately one-third of patients taking biologic agents use them as
monotherapy, in spite that combination therapy with Disease Modifying Drugs is more efficacious than
monotherapy. The aim of our study was to assess the prevalence of biologics monotherapy in a cohort of patients
with RA followed at a single center, and to analyze the reasons for monotherapy, including patients with
prescriptions that do not take the medication.
Methods: All patients with Rheumatoid Arthritis, with biologic therapy followed at our Rheumatology Unit were
included. Prevalence and reasons for biologics monotherapy was calculated in general, for each biologic course and
for each biologic. Prescription data was obtained from the Electronic Medical Record, and drugs acquisition was
obtained from the Hospital Administrative database. Drug survival was also calculated and compared between
monotherapy and combination therapy.
Results: Seventy nine patients with 115 courses of biologic treatments were included. In 40 (35 %, 95 % CI:
26–44 %) of all biologics courses, biologics were initiated as monotherapy. In 27 courses (23 %, 95 % CI: 16–32 %)
biologic monotherapy was prescribed by the treating rheumatologists, and in the other 13 (11 %, 95 % CI: 6–18 %)
it was initiated as such by decision of the patient regardless of the physician indication. Reasons for prescription of
biologic monotherapy by the treating rheumatologists were adverse events with previous DMARDs in 55.5 %, and
was not specified in the remaining courses. Only 25 % of biologics’ courses were monotherapy from the beginning
to the end of the biologic therapy. The overall survival on biologics was 45 % (95 % CI: 35–55 %) at 3 years. There
were no statistically differences in biologics survival by modality (monotherapy vs combination) (p = 0.543), course
(p = 0.4454), or by biologic drug (p = 0.9612).
Conclusions: Almost 1/3 of patients on biologics use them as monotherapy. This is due to physician’s preferences
in 60 % of the cases, and to patients not compliance with the indication in around 40 % of the cases. Better
communications is needed to assure that physicians and patients agree on the prescribed and used medication.
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Background
The importance of early therapeutic intervention to re-
lieve symptoms, prevent newly evolving joint erosions
and joint space narrowing, improve functional abilities
and quality of life in patients with active RA is well
established [1, 2]. The conventional DMARD MTX is
the standard of care for patients with RA, however there
is still a substantial number of patients that do not
respond to MTX [1, 3]. On the other hand there are pa-
tients with RA that are intolerant to MTX, drug interac-
tions preclude the use of MTX with certain medications,
and some patients experience toxicity or adverse events.
The efficacy of biologic agents in combination with
MTX is well established and that appears to be the most
effective regimen currently available for patients with
early or established RA who have failed to respond to
traditional DMARDs [2]. However, biologic monother-
apy is commonly used in clinical practice. Data from
biologic registries and US claims databases indicate that
approximately 30 % of patients taking biologics use them
as monotherapy [4–7]. However, this figure does not
capture patients who fill prescriptions but do not take
some or all of the medication [6]. Many patients in
whom MTX or other traditional DMARDs are pre-
scribed in combination with biologics decide not to take
them, very often, without telling their Rheumatologist.
In an online survey of 1500 patients, 45 % admitted to
being less than forthright with their rheumatologists [8].
The purpose of our study was to assess the prevalence
of biologics monotherapy in a cohort of patients with
RA followed at a single center, and to analyze the rea-
sons for monotherapy, including patients with prescrip-
tions that do not take the medication.
Methods
All patients with RA affiliated to the Hospital Italiano de
Buenos Aires Health Management Organization (Plan
de Salud) treated with biologics were included, in a
retrospective observational cohort study.
Patients fulfilled RA 1987 [9] or 2010 [10, 11] classifi-
cation criteria, and were treated with one of the follow-
ing biologic agents: TNF inhibitors (TNFi) (infliximab,
etanercept, adalimumab, certolizumab-pegol or golimu-
mab), anti-CD20 antibody (rituximab), a cytotoxic T
lymphocyte antigen-4 fusion protein (abatacept) or an
IL-6 receptor (IL-6R) antagonist (tocilizumab).
All patients with biologic treatment without excep-
tions, are register in our Unit’s registry of biologics, and
in the HMO administrative databases,, as it is a require-
ment to get the therapy. Treatment was decided by the
treating rheumatologists, according to National guide-
lines. Patients must fail at least one DMARD to receive
biologic therapy. The clinical data of all patients in-
cluded was reviewed and extracted from ours Hospital
Electronic Medical records and our register. Demo-
graphic data, dates on diagnostic, initial prescription of
DMARD therapy (DMARDs included were: Methotrex-
ate, leflunomide, sulfasalazine, and Hydroxychloroquine),
initial prescription of biologics, subsequent change of
DMARD (on top of the biologic), reasons for the change,
and last visit on follow up were collected. The number
of DMARDs and biologics actually acquired by each pa-
tient were captured from the HMO administrative data-
bases, in order to assess the compliance of each patient
with the prescribed medication during the 6–12 months
before and after the acquisition of the prescribed bio-
logic drug. All medications acquired by patients affiliated
to our HMO are registered in the HMO administrative
database, without exception. Patients could only acquire
DMARDs and biologics in Argentina with a prescription.
Hospital Italiano HMO has their own pharmacies, where
medications prescribed are sold to the patients at a
lower cost, and all transactions are registered in the
HMO administrative data base. Patients could also buy
their medications in other pharmacies adhered to the
Hospital Italiano HMO, where they buy them with an
important discount of 40 to 50 % of medication price,
and this transaction is also registered in the Hospital
Italiano HMO administrative database. Medications that
are used chronically are prescribed by the treating physi-
cians in the electronic medical records, and usually ac-
quired by the patients at the HMO’s pharmacies. The
only circumstance in which a medication acquired by a
patient would not be registered is if the patients buys it
in a private pharmacy paying the medication full price.
HMO’s private studies and surveys (unpublished infor-
mation) have shown that 70 % of chronic medications
are acquired in the HMO pharmacies, and that 98 % of
all medications are acquired within the HMO system.
The study was conducted according to the Declar-
ation of Helsinki and local regulations. Ethical ap-
proval for the study was obtained from the Hospital
local Ethics Committee (comité de ética y protocolos
Table 1 Baseline patient characteristics
Patient characteristics Total population
Sex, n female (%) 71 (92)
Mean age, years (SD) 62.7 (14)
Mean disease duration, years (SD) 14 (9.1)
Mean DAS28 (SD) 5.47 (0.84)
Mean HAQ (SD) 1.4 (1.2)
Rheumatoid factor positive, % 92
Anti CCP antibodies positive, % 75,3
Median follow up (IQ range), Yrs 1.2 (0.5–3)
Median number of DMARDs before
biologics (IQ range)
2 (1–3)
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de investigación (CEPI). As data was obtained from
Electronic Medical Records, and administrative data,
the Ethics committee considered that an informed
consent was not needed. All patients at entrance to
the Hospital Italiano HMO signed an informed con-
sent authorizing the use of their data for clinical
research.
Statistical analysis
The prevalence of monotherapy was calculated with
its 95 % confidence intervals, in general and for each
biologic drug and for each treatment course. Analysis
was done at course treatment level, (a patient with
more than one course of biologic treatment was in-
cluded more than once in this analysis). A biologic
treatment course was defined as the use of the bio-
logic drug since first prescribed until the drug was
definitively stopped (if the drug was temporarily dis-
continued it was considered the same treatment
course). First course was the first biologic prescribed,
second course was the second biologic prescribed,
etc.
Biologics monotherapy at initiation of the biologic
treatment was defined in two different ways:
1) Prescribed monotherapy: course of treatment in
which the treating Rheumatologist prescribed the
biologic without concomitant DMARD; data
obtained from the Electronic Medical Record.
2) Actual monotherapy: patients taking biologic as
monotherapy in that course of treatment,
independently of the treating Rheumatologist
prescription, as obtained by data on DMARDs
acquisition from HMO administrative database;
3) Prevalence of monotherapy during the complete
biologic treatment was also calculated, as some
patients started biologics monotherapy but then a
DMARD was added.
Reasons for monotherapy was listed and categorized in
toxicity/intolerance to DMARD, reluctance of the pa-
tients to receive concomitant DMARDs and Physician
decision.
Kaplan–Meier survival curves on different biologics
and for patients in monotherapy and in combination,
using Breslow (generalized Wilcoxon) test for compari-
son among different groups were constructed. In
addition, the median (IQR) durations of intake of vari-
ous biologics and between monotherapy and combin-
ation therapy was compared using Kruskal Wallis test. A
p-value < 0.05 was considered to be significant for all
statistical comparisons
Results
Seventy-nine patients with 115 courses of biologic treat-
ments were included. Patients’ characteristics are shown
in Table 1. All patients have received at least one
DMARD before biologics. Most patients (54 %) were re-
ceiving combination therapy (of which the most frequent
combination was MTX plus LFN) at the time of starting
biologics, 27 % were receiving MTX monotherapy and
11 % were receiving LFN monotherapy.
Taking into account all courses of biologic treatments,
in 40 (35 %, 95 % CI: 26–44 %) biologics were initiated
Table 2 Percentage of patients on monotherapy according to treatment course and drug
1st Course 2nd Course 3rd Course 4th Course Total
Number of patients 79 25 9 2 115
% Patients on biologic monotherapy at initiation
of biologics (95 % CI)
24 (15–35) 60 (39–79) 44 (14–79) 100 35 (26–44)
% Patients on biologic monotherapy at initiation
of biologics due to Medical prescription (95 % CI)
15 (8–25) 48 (28–69) 33 (7–70) 0 (0) 23 (16–32)
% Patients biologic monotherapy at initiation of
biologics, due to patient’s decision (95 % CI)
9 (3.6–17) 12 (2.5–31) 11 (0.2–48) 100 11 (6–18)
Table 3 Percentage of patients on monotherapy according to the biologic treatment
1st Course 2nd Course 3rd Course 4th Course Total
N Patients on adalimumab monotherapy/patients on adalimumab (%) 5/27 (18) 2/3(67) - - 7/30 (23)
N patients on etanercept monotherapy/patients on etanercept (%) 12/39 (31) 4/6 (67) 1/1 (100) - 17/46 (37)
N patients on Infliximab monotherapy/patients on Infliximab (%) 0/7(0) 1/1 (100) 0/0 0/0 1/8 (12)
N patients on Abatacept monotherapy/patients on Abatacept (%) 1/1 (100) 6/10 (60) 0/3 (0) 1/1 (100) 8/15 (53)
N patients on Rituximab monotherapy/patients on Rituximab (%) 1/5 (20) 0/2 (0) 0/1 (0) 1/1 (100) 2/9 (22)
N patients on Tocilizumab monotherapy/patients on Tocilizumab (%) 0/0 (0) 2/2 (100) 3/4 (75) 0/0 (0) 5/6 (83)
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as monotherapy. In 27 courses (23 %, 95 % CI: 16–32 %)
biologic monotherapy was prescribed by the treating
rheumatologists, and in the other 13 (11 %, 95 % CI: 6–
18 %) it was initiated as such by decision of the patient
regardless of the physician indication (Tables 2 and 3).
Reasons for prescription of biologic monotherapy by the
treating rheumatologists were adverse events with previ-
ous DMARDs in 15/27 courses (55.5 %), and was not
specified in the remaining coues. There were some dif-
ferences among the different biologics related to the per-
centage of monotherapy that was due to rheumatologists
prescription compared to patient’s decision. TNFi, rituxi-
mab, abatacept and tocilizumab were prescribed as
monotherapy by the treating rheumatologist in 77 %,
50 %, 25 % and 60 % of the courses of monotherapy re-
spectively. Some patients that initiated the biologic
course as monotherapy added traditional DMARDs dur-
ing treatment. Only 29/115 (25 %) courses of biologic
therapy were as monotherapy from the beginning to the
end of the biologic therapy. Among the 40 monotherapy
courses, 29 (72.5 %) continued as monotherapy for the
complete course, while in the others a traditional
DMARD was added (Table 4). On the other hand some
patients initiated MTX with biologic therapy in combin-
ation, and subsequently discontinue it due to adverse
events, or other causes, so we also looked at the preva-
lence of monotherapy with biologics at the end of the
biologic course (or last follow up for those patients not
stopping/switching biologics) that was 33 % (95 % CI:
24–42) (Table 5).
Median follow up of this cohort was 1.2 years (IQR:
0.5–3). The overall survival on biologics was 45 % (95 %
CI: 35–55 %) at 3 years and 39 % (95 % CI: 28–50 %) at
4 years. The survival by biologic are shown in Table 6.
There were no statistically differences in biologics
survival by course (p = 0.4454), or by biologic drug
(p = 0.9612). There were no statistical differences on
drug survival at 3 years between patients on mono-
therapy throughout the complete course and those
with combined therapy (58 %; 95 % CI: 37–74, vs
52 %; 95 % CI: 39–63, respectively) (Fig. 1).
Discussion
Concurrent use of MTX and a biologic is generally the
standard-of-care in patients with RA who continue with
disease activity despite MTX. Many patients, however,
do not take MTX concomitantly as prescribed. This
figure however is not clear, as few studies have investi-
gated that prevalence.
We found that 35 % of patients started their biologic
therapy as monotherapy. Among them 11 % used mono-
therapy because they did not take traditional DMARDs
concomitantly as prescribed, 23 % of patients initiating a
biologic therapy did so as monotherapy due to the
Rheumatologist prescription.
A recent study on 6744 patient records in private and
public practice in Canada showed that among patients
on their first biologics, 45 % did not purchase a
DMARD. By contrast, physicians reported that they pre-
scribed a DMARD with a biologic in 80–90 % of patients
[6, 12]. Another study on 1652 patient records also in
Canada showed biologic monotherapy prescribing rate
of 12 %, but 29 % did not acquired their DMARD within
6 months after starting biologic therapy [6, 13]. In the
Table 4 Percentage of patients on monotherapy during the complete biologic course, according to biologic treatment course
1st Course 2nd Course 3rd Course 4th Course Total
Number of patients 79 25 9 2 115
% Patients on biologic monotherapy during the
complete biologic course (95 % CI)
15 (8–25) 48 (28–69) 44 (14–79) 50 (13–99) 25 (18–34)
% Patients on biologic monotherapy during the complete
biologic course due to Medical prescription (95 % CI)
10 (4–19) 40 (21–61) 33 (7–70) 0 18 (12–26)
% Patients biologic monotherapy during the complete
biologic course due to patient’s decision (95 % CI)
5 (1–12) 8 (1–26) 11 (0.2–48) 50 (13–99) 7 (3–13)
Table 5 Percentage of patients on monotherapy at the end of biologic course, according to the biologic treatment course
1st Course 2nd Course 3rd Course 4th Course Total
Number of patients 79 25 9 2 115
% Patients on biologic monotherapy at the end
of the course (95 % CI)
25 (16–36) 52 (31–72) 44 (14–79) 50 (13–99) 33 (24–42)
% Patients on biologic monotherapy at the end
of the course due to Medical prescription (95 % CI)
20 (12–31) 40 (21–61) 33 (7–70) 50 (13–99) 25 (17–34)
% Patients biologic monotherapy at the end of
the course due to patient’s decision (95 % CI)
5 (1–12) 12 (2.5–31) 11 (0.3–48) 0 8 (4–14)
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US, Yazici et al. found that 30 % of patients initiating bi-
ologics did that as monotherapy in a study involving a
large database of patients with newly diagnosed RA [7].
Only 42 % of patients had filled a traditional DMARD
prescription during the 6 months prior to initiating the
TNFi. In summary, these studies showed that a high per-
centage of patients did not purchase the prescribed
DMARD when they are taking biologics.
In a US study of 7074 biologic naïve patients, found
that up to 31 % of patients receiving an anti TNF agent
in the real word received it as monotherapy [14].
In CORRONA registry on 9905 patients, 25 % received
biologic monotherapy. Among patients that were previ-
ously biologic naïve, 19 % initiated a biologic as mono-
therapy, whereas monotherapy initiation rates for
patients who received one prior biologic was 29 %; two
prior biologics 26 %; and three or more prior biologics
31 %. Prior biologic experience and individual physician’s
prescribing patterns were associated with increased like-
lihood of initiating a biologic as monotherapy [15].
Interestingly in our study physicians, more often
prescribed Biologics as monotherapy in the 2nd and
3rd biologic course than in the 1st (48, 33 and 15 %
respectively). However, the number of patients not
purchasing the traditional DMARD was similar
among all treatment courses (9, 12 and 11 % for the
1st, 2nd, and 3rd courses respectively). Survival on
drug therapy was shorter than in clinical trials, but
similar to that found in some other registries. We did
not find differences on drug survival among patients
on biologic monotherapy and combination therapy,
but our study was underpowered to detect such dif-
ferences. More than 2000 patients would be required
to show significant statistical differences with the sur-
vival rate we found. Survival on drug therapy in some
way is a surrogate of efficacy and absence of toxicity.
In that sense as we do not have data on efficacy,
survival on the drugs seemed to be showing similar
efficacy for patients on combination and on
monotherapy.
Our study has some strength. We combined clinical
records with full administrative data, providing informa-
tion on actual use of concomitant DMARDs. We also in-
cluded data from different treatment courses, showing
that with each biologic course patients are more willing
to receive the biologic treatment as monotherapy. On
the other side our study has some weakness, mainly the
small number of patients and short time of follow up,
and the lack of data on efficacy. Another weakness is
that this is a single center study, so results might not be
extrapolated to other settings.
Table 6 Drug survival by biologic drug
Biologic drug Interval % biologics’ survival (95 % CI)
Etanercept 3 years 59 (41–73)
Infliximab 3 years 20 (2–52)
Adalimumab 3 years 54 (33–70)
Rituximab 3 years 45 (10–75)
Abatacept 3 years 63 (33–83)
Tocilizumab 2 years 75 (13–96)
Fig. 1 Biologics survival by Biologic therapy modality: Monotherapy throughout all the course of biologic therapy vs biologic therapy combined
with DMARDs
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Conclusions
In summary we found that almost 1/3 of patients on
biologics use them as monotherapy. This is due to physi-
cian’s preferences in 60 % of the cases, and to patients
not compliance with the indication in around 40 % of
the cases. Better communications is needed to assure
that physicians and patients agree on the prescribed and
used medication.
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